Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites.

Structure activity relationships (SAR), three-dimensional structure activity relationships (3D-QSAR), and pharmacophores represent useful tools in understanding cytochrome P450 (CYP) active sites in the absence of crystal structures for these human enzymes. These approaches have developed over the last 30 years such that they are now being applied in numerous industrial and academic laboratories solely for this purpose. Such computational approaches have helped in understanding substrate and inhibitor binding to the major human CYPs 1A2, 2B6, 2C9, 2D6, 3A4 as well as other CYPs and additionally complement homology models for these enzymes. Similarly, these approaches may assist in our understanding of CYP induction. This review describes in detail the development of pharmacophores and 3D-QSAR techniques, which are now being more widely used for modeling CYPs; the review will also describe how such approaches are likely to further impact our active site knowledge of these omnipresent and important enzymes.

[1]  N. Vermeulen,et al.  Computer prediction and experimental validation of cytochrome P4502D6-dependent oxidation of GBR 12909. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[2]  C Masimirembwa,et al.  Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function. , 2000, Biochemical and biophysical research communications.

[3]  T. Shimizu,et al.  Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone , 1999, Clinical pharmacology and therapeutics.

[4]  D. Lewis,et al.  On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human p450 substrate specificity and metabolism. , 2000, Biochemical pharmacology.

[5]  Gabriele Cruciani,et al.  Three-Dimensional Quantitative Structure-Properties Relationships , 2003 .

[6]  J. Halpert,et al.  Molecular basis of P450 inhibition and activation: implications for drug development and drug therapy. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[7]  Robert L. Haining,et al.  Enzymatic Determinants of the Substrate Specificity of CYP2C9: Role of B‘−C Loop Residues in Providing the π-Stacking Anchor Site for Warfarin Binding† , 1999 .

[8]  Ferran Sanz,et al.  THEORETICAL STUDY ON THE METABOLISM OF CAFFEINE BY CYTOCHROME P-450 1A2 AND ITS INHIBITION , 1994 .

[9]  J. Idle,et al.  The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. , 1994, Pharmacogenetics.

[10]  C Skoda,et al.  The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.

[11]  S. Ekins,et al.  Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. , 1999, The Journal of pharmacology and experimental therapeutics.

[12]  S. Ekins,et al.  Progress in predicting human ADME parameters in silico. , 2000, Journal of pharmacological and toxicological methods.

[13]  M H Tarbit,et al.  Molecular modelling of lanosterol 14 alpha-demethylase (CYP51) from Saccharomyces cerevisiae via homology with CYP102, a unique bacterial cytochrome P450 isoform: quantitative structure-activity relationships (QSARs) within two related series of antifungal azole derivatives. , 1999, Journal of enzyme inhibition.

[14]  L. Moore,et al.  St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  György G. Ferenczy,et al.  The active site of cytochrome P-450 nifedipine oxidase: a model-building study. , 1989, Journal of molecular graphics.

[16]  C. Hansch,et al.  QSAR of P450 oxidation: on the value of comparing kcat and km with kcat/km. , 1996, Drug metabolism reviews.

[17]  Francesca Fanelli,et al.  Theoretical investigation of substrate specificity for cytochromes P450 IA2, P450 IID6 and P450 IIIA4 , 2000, J. Comput. Aided Mol. Des..

[18]  D. Mansuy,et al.  Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9. , 1996, Biochemistry.

[19]  Wannian Zhang,et al.  A three-dimensional model of lanosterol 14α-demethylase of Candida albicans , 1998 .

[20]  A. Parkinson,et al.  Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. , 1997, Archives of biochemistry and biophysics.

[21]  C. Hansch,et al.  Quantitative structure-activity relationships of cytochrome P-450. , 1993, Drug metabolism reviews.

[22]  M H Tarbit,et al.  Molecular modelling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals. , 1996, Xenobiotica; the fate of foreign compounds in biological systems.

[23]  F. Guengerich,et al.  Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. , 1993, Journal of medicinal chemistry.

[24]  M. van den Berg,et al.  Structure-dependent induction of CYP1A by polychlorinated biphenyls in hepatocytes of cynomolgus monkeys (Macaca fascicularis). , 1999, Toxicology and applied pharmacology.

[25]  Vithal M. Kulkarni,et al.  Development of Pharmacophore Alignment Models as Input for Comparative Molecular Field Analysis of a Diverse Set of Azole Antifungal Agents , 1999, J. Chem. Inf. Comput. Sci..

[26]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[27]  S. Horvat,et al.  Characterization of the mouse lanosterol 14alpha-demethylase (CYP51), a new member of the evolutionarily most conserved cytochrome P450 family. , 2000, Archives of biochemistry and biophysics.

[28]  P. Ortiz de Montellano,et al.  Active site topology of human cytochrome P450 2E1. , 1996, Chemical research in toxicology.

[29]  D. Mansuy,et al.  The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. , 1995, Biochemistry.

[30]  S. Grimm,et al.  Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[31]  D. Lewis,et al.  Quantitative structure-activity relationships in substrates, inducers, and inhibitors of cytochrome P4501 (CYP1). , 1997, Drug metabolism reviews.

[32]  J. Venhorst,et al.  Design, synthesis, and characterization of 7-methoxy-4-(aminomethyl)coumarin as a novel and selective cytochrome P450 2D6 substrate suitable for high-throughput screening. , 1999, Chemical research in toxicology.

[33]  S. Wrighton,et al.  The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.

[34]  C. Hansch Quantitative Relationships Between Lipophilic Character and Drug Metabolism , 1972 .

[35]  B C Finzel,et al.  Crystal structure of substrate-free Pseudomonas putida cytochrome P-450. , 1986, Biochemistry.

[36]  W. Legrum,et al.  Approach to Detect Substrates Suitable to Measure the Coumarin 7‐Hydroxylase (Cyp 2a‐5) ‐ Structure‐Activity Relationships , 1994, Archiv der Pharmazie.

[37]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[38]  Barry C. Jones,et al.  Properties of cytochrome P450 isoenzymes and their substrates Part 1: active site characteristics , 1997 .

[39]  M. Waterman,et al.  Characterization and catalytic properties of the sterol 14alpha-demethylase from Mycobacterium tuberculosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Miners,et al.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.

[41]  S A van Acker,et al.  A predictive model for substrates of cytochrome P450-debrisoquine (2D6). , 1992, Chemical research in toxicology.

[42]  Vithal M. Kulkarni,et al.  Three-Dimensional Quantitative Structure-Activity Relationship (QSAR) and Receptor Mapping of Cytochrome P-45014DM Inhibiting Azole Antifungal Agents1 , 1999, J. Chem. Inf. Comput. Sci..

[43]  S. Ekins,et al.  Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. , 1999, Pharmacogenetics.

[44]  N. Vermeulen,et al.  A refined substrate model for human cytochrome P450 2D6. , 1997, Chemical research in toxicology.

[45]  J. Lehmann,et al.  An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway , 1998, Cell.

[46]  Maurizio Recanatini,et al.  Comparative molecular field analysis of non-steroidal aromatase inhibitors related to fadrozole , 1996, J. Comput. Aided Mol. Des..

[47]  P. Maurel,et al.  Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P450. , 1996, Biochemical pharmacology.

[48]  J. G. Snijders,et al.  Extension of a predictive substrate model for human cytochrome P4502D6. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[49]  D A Smith,et al.  Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. , 1992, Biochemical pharmacology.

[50]  Jon A. Erickson,et al.  A comparative molecular field analysis study of obtusifoliol 14α-methyl demethylase inhibitors † , 1999 .

[51]  F. Sanz,et al.  Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. , 1993, Molecular pharmacology.

[52]  C. Hansch,et al.  Structure--activity correlations in the metabolism of drugs. , 1968, Archives of biochemistry and biophysics.

[53]  A. Alex,et al.  Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.

[54]  D. Lewis,et al.  Molecular modelling and quantitative structure-activity relationship studies on the interaction of omeprazole with cytochrome P450 isozymes. , 1998, Toxicology.

[55]  Eric F. Johnson,et al.  Engineering Microsomal Cytochrome P450 2C5 to Be a Soluble, Monomeric Enzyme , 2000, The Journal of Biological Chemistry.

[56]  Antti Poso,et al.  A comparative molecular field analysis of cytochrome P450 2A5 and 2A6 inhibitors , 2001, J. Comput. Aided Mol. Des..

[57]  T Ishizaki,et al.  Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes. , 2003, British journal of clinical pharmacology.

[58]  M H Tarbit,et al.  Structural determinants of cytochrome P450 substrate specificity, binding affinity and catalytic rate. , 1998, Chemico-biological interactions.

[59]  T. Theophanides,et al.  Molecular modeling of azole antifungal agents active against Candida albicans. 1. A comparative molecular field analysis study. , 1996, Journal of medicinal chemistry.

[60]  G. Szklarz,et al.  Molecular modeling of mammalian cytochromes P450: application to study enzyme function. , 2000, Vitamins and hormones.

[61]  Wannian Zhang,et al.  A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals. , 2000, Journal of medicinal chemistry.

[62]  D A Smith,et al.  Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase). , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[63]  S. Loft,et al.  Fluvoxamine is a potent inhibitor of cytochrome P4501A2. , 1993, Biochemical pharmacology.

[64]  N. Vermeulen,et al.  Modeling the active sites of cytochrome P450s and glutathione S-transferases, two of the most important biotransformation enzymes. , 1997, Drug metabolism reviews.

[65]  D E McRee,et al.  Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. , 2000, Molecular cell.

[66]  G. Tucker,et al.  Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[67]  Jeffrey P. Jones,et al.  Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[68]  Tudor I. Oprea,et al.  Three-dimensional quantitative structure-activity relationships of steroid aromatase inhibitors , 1996, J. Comput. Aided Mol. Des..

[69]  W. Trager,et al.  Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding. , 1999, Biochemistry.

[70]  G. Nelsestuen,et al.  Steady state enzyme velocities that are independent of [enzyme]: an important behavior in many membrane and particle-bound states. , 1997, Biochemistry.

[71]  A. Alex,et al.  A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.

[72]  Jeffrey P. Jones,et al.  A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions. , 2000, Journal of medicinal chemistry.

[73]  J. Lehmann,et al.  The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. , 1998, The Journal of clinical investigation.

[74]  M H Tarbit,et al.  Molecular modelling of CYP2B6, the human CYP2B isoform, by homology with the substrate-bound CYP102 crystal structure: evaluation of CYP2B6 substrate characteristics, the cytochrome b5 binding site and comparisons with CYP2B1 and CYP2B4. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[75]  T. Fujita Recent Success Stories Leading to Commercializable Bioactive Compounds with the Aid of Traditional QSAR Procedures , 1997 .

[76]  Jeffrey P. Jones,et al.  Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. , 1999, Archives of biochemistry and biophysics.

[77]  Dennis A. Smith,et al.  Properties of cytochrome P450 isoenzymes and their substrates Part 2: properties of cytochrome P450 substrates , 1997 .

[78]  C. Waller,et al.  Modeling the cytochrome P450-mediated metabolism of chlorinated volatile organic compounds. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[79]  F. Guengerich,et al.  Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. , 1985, Cancer research.

[80]  J Guillon,et al.  New aromatase inhibitors. Synthesis and biological activity of aryl-substituted pyrrolizine and indolizine derivatives. , 2000, Bioorganic & medicinal chemistry.

[81]  S. Ekins,et al.  Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[82]  O. Gotoh,et al.  Sterol 14-demethylase P450 (CYP51) provides a breakthrough for the discussion on the evolution of cytochrome P450 gene superfamily. , 2000, Biochemical and biophysical research communications.

[83]  M J Sternberg,et al.  A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. , 1991, Carcinogenesis.

[84]  C. Yoon,et al.  Structure-related inhibition of human hepatic caffeine N3-demethylation by naturally occurring flavonoids. , 1998, Biochemical pharmacology.

[85]  N. Vermeulen,et al.  A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108. , 1996, Chemical research in toxicology.

[86]  T. Sueyoshi,et al.  The Nuclear Orphan Receptor CAR-Retinoid X Receptor Heterodimer Activates the Phenobarbital-Responsive Enhancer Module of the CYP2B Gene , 1998, Molecular and Cellular Biology.

[87]  D. Kelly,et al.  Characteristics of the heterologously expressed human lanosterol 14α‐demethylase (other names: P45014DM, CYP51, P45051) and inhibition of the purified human and Candida albicans CYP51 with azole antifungal agents , 1999, Yeast.

[88]  S. Ekins,et al.  Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. , 1999, The Journal of pharmacology and experimental therapeutics.

[89]  M. Pincus,et al.  Molecular modeling of mammalian cytochrome P450s , 2000, Cellular and Molecular Life Sciences CMLS.

[90]  M. Kirby,et al.  Fallen arches, or how the vertebrate got its head. , 1998, The Journal of clinical investigation.

[91]  B C Finzel,et al.  The 2.6-A crystal structure of Pseudomonas putida cytochrome P-450. , 1985, The Journal of biological chemistry.

[92]  P. Maurel,et al.  Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[93]  Ferran Sanz,et al.  3D-QSAR methods on the basis of ligand–receptor complexes. Application of COMBINE and GRID/GOLPE methodologies to a series of CYP1A2 ligands , 2000, J. Comput. Aided Mol. Des..

[94]  Z. Simon,et al.  Theoretical Investigations on the Role of Steroid-Skeleton C4 = C5 Unsaturation in Competitive Aromatase Inhibition , 1989, Zeitschrift fur Naturforschung. C, Journal of biosciences.

[95]  Grazyna D. Szklarz,et al.  Molecular modeling of cytochrome P450 3A4 , 1997, J. Comput. Aided Mol. Des..

[96]  Antti Poso,et al.  Comparative Molecular Field Analysis of Compounds with CYP2A5 Binding Affinity , 1995 .

[97]  S. Ekins,et al.  The role of CYP2B6 in human xenobiotic metabolism. , 1999, Drug metabolism reviews.

[98]  Gianpaolo Bravi,et al.  Application of MS‐WHIM Descriptors: 1. Introduction of New Molecular Surface Properties and 2. Prediction of Binding Affinity Data , 2000 .

[99]  Anton J. Hopfinger,et al.  Molecular Shape and QSAR Analyses of a Family of Substituted Dichlorodiphenyl Aromatase Inhibitors , 1994, J. Chem. Inf. Comput. Sci..

[100]  A. Cavalli,et al.  Comparative molecular field analysis of non-steroidal aromatase inhibitors: an extended model for two different structural classes. , 1998, Bioorganic & medicinal chemistry.

[101]  D. Lewis,et al.  Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles. , 2000, Toxicology.

[102]  S. Ekins,et al.  Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors. , 1999, The Journal of pharmacology and experimental therapeutics.

[103]  V. Kulkarni,et al.  Three-dimensional quantitative structure-activity relationship (QSAR) and receptor mapping of cytochrome P-450(14 alpha DM) inhibiting azole antifungal agents. , 1999, Journal of chemical information and computer sciences.

[104]  K. Chiba,et al.  Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. , 1998, British journal of clinical pharmacology.

[105]  J. Halpert,et al.  Use of homology modeling in conjunction with site-directed mutagenesis for analysis of structure-function relationships of mammalian cytochromes P450. , 1997, Life sciences.

[106]  J. Venhorst,et al.  Influence of N-substitution of 7-methoxy-4-(aminomethyl)-coumarin on cytochrome P450 metabolism and selectivity. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[107]  P. Ortiz de Montellano,et al.  Active site topology of Saccharomyces cerevisiae lanosterol 14 alpha-demethylase (CYP51) and its G310D mutant (cytochrome P-450SG1). , 1992, The Journal of biological chemistry.

[108]  K. Korzekwa,et al.  Predicting the cytochrome P450 mediated metabolism of xenobiotics. , 1993, Pharmacogenetics.

[109]  A. P. Koley,et al.  Conformational modulation of human cytochrome P450 2E1 by ethanol and other substrates: a CO flash photolysis study. , 2000, Biochemistry.

[110]  E. Schuetz,et al.  Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. , 1996, Molecular pharmacology.